Sotac Pharmaceuticals Ltd

Sotac Pharma. Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Sotac Pharmaceuticals Ltd

₹ 111 0.00%
29 May - close price
sotacpharma.com NSE - SME: SOTAC
About

Incorporated in 2015, Sotac Pharmaceuticals
Ltd manufactures and sells a wide range of pharmaceutical products[1]

Key Points

Business Overview:[1]
SPL specializes in manufacturing a broad range of pharmaceutical products across various therapeutic areas, including anti-diabetic, anti-psychotic, vitamins, minerals, iron supplements, anti-cold, anti-allergic, dermatological treatments, antacids, anti-ulcer (PPI), anti-emetics, cardiac, antihypertensives, analgesic, antipyretic, anti-inflammatory, antibacterial, antiviral, general antibiotics (β-lactams and non-β-lactams), antifungal, and cephalosporins.

Website NSE - SM
  • Market Cap ₹ 123 Cr.
  • Current Price ₹ 111
  • High / Low ₹ 152 / 100
  • Stock P/E 24.9
  • Book Value ₹ 52.3
  • Dividend Yield 0.09 %
  • ROCE 12.2 %
  • ROE 8.88 %
  • Face Value ₹ 10.0
Edit ratios

Pros

  • Company has reduced debt.

Cons

  • The company has delivered a poor sales growth of 10.6% over past five years.
  • Company has a low return on equity of 11.1% over last 3 years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of Nifty SME Emerge

Edit Columns
Loading peers table ...

Half Yearly Results

Standalone Figures in Rs. Crores / View Consolidated

Mar 2022 Sep 2022 Mar 2023 Sep 2023 Mar 2024 Sep 2024 Mar 2025 Sep 2025 Mar 2026
39.25 30.75 27.24 33.11 33.99 30.61 31.77 24.80 47.08
36.50 25.68 24.10 28.16 28.75 26.99 27.70 20.55 42.21
Operating Profit 2.75 5.07 3.14 4.95 5.24 3.62 4.07 4.25 4.87
OPM % 7.01% 16.49% 11.53% 14.95% 15.42% 11.83% 12.81% 17.14% 10.34%
0.03 0.11 0.13 0.52 0.57 0.92 1.45 1.10 1.00
Interest 0.29 0.42 0.44 0.54 0.48 0.50 0.67 1.01 0.78
Depreciation 0.62 0.74 0.89 1.10 1.41 1.20 1.27 1.21 1.29
Profit before tax 1.87 4.02 1.94 3.83 3.92 2.84 3.58 3.13 3.80
Tax % 25.67% 23.13% 27.84% 25.07% 26.79% 25.35% 25.42% 25.24% 32.11%
1.40 3.09 1.40 2.88 2.87 2.12 2.66 2.33 2.59
EPS in Rs 6.09 13.43 1.74 2.61 2.60 1.92 2.41 2.11 2.34
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
23.41 28.68 43.44 73.15 57.98 67.11 62.38 71.88
21.46 26.70 40.58 65.13 49.73 56.91 54.70 62.76
Operating Profit 1.95 1.98 2.86 8.02 8.25 10.20 7.68 9.12
OPM % 8.33% 6.90% 6.58% 10.96% 14.23% 15.20% 12.31% 12.69%
0.34 0.69 0.35 -1.63 0.24 1.09 2.38 2.10
Interest 0.49 0.37 0.61 0.58 0.90 1.02 1.17 1.79
Depreciation 1.04 1.07 1.11 1.13 1.63 2.51 2.47 2.50
Profit before tax 0.76 1.23 1.49 4.68 5.96 7.76 6.42 6.93
Tax % 0.00% 0.00% 0.00% 29.91% 24.66% 25.90% 25.55% 29.00%
0.76 1.23 1.48 3.30 4.50 5.75 4.77 4.92
EPS in Rs 8.00 5.35 6.43 14.35 5.59 5.20 4.32 4.45
Dividend Payout % 0.00% 0.00% 0.00% 13.94% 0.00% 0.00% 0.00% 0.00%
Compounded Sales Growth
10 Years: %
5 Years: 11%
3 Years: 7%
TTM: 15%
Compounded Profit Growth
10 Years: %
5 Years: 27%
3 Years: 3%
TTM: 3%
Stock Price CAGR
10 Years: %
5 Years: %
3 Years: -4%
1 Year: -8%
Return on Equity
10 Years: %
5 Years: 15%
3 Years: 11%
Last Year: 9%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity Capital 0.95 2.30 2.30 2.30 8.05 11.05 11.05 11.05
Reserves -0.04 1.40 2.51 4.80 12.94 37.22 41.98 46.77
8.11 7.24 6.68 7.39 10.66 11.17 20.13 12.09
7.45 10.43 11.01 21.82 23.13 16.64 12.13 24.70
Total Liabilities 16.47 21.37 22.50 36.31 54.78 76.08 85.29 94.61
7.54 6.41 6.42 8.80 14.09 17.67 16.66 18.08
CWIP 0.00 0.00 0.00 0.00 0.04 0.05 0.20 1.71
Investments 0.00 0.00 0.00 0.00 4.00 11.50 13.33 12.18
8.93 14.96 16.08 27.51 36.65 46.86 55.10 62.64
Total Assets 16.47 21.37 22.50 36.31 54.78 76.08 85.29 94.61

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
2.22 3.58 8.54 -19.75 -6.08 12.15
-1.07 -3.28 -10.93 -12.53 -1.89 -2.30
-1.17 -0.30 11.97 23.32 7.78 -9.96
Net Cash Flow -0.02 0.00 9.57 -8.96 -0.20 -0.11
Free Cash Flow 1.09 0.08 1.58 -25.85 -7.71 6.80
CFO/OP 26% 62% 124% -177% -69% 154%

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 72.81 107.92 52.68 62.57 72.40 119.71 144.41 146.19
Inventory Days 42.90 39.50 40.71 35.14 87.26 88.99 84.58 112.22
Days Payable 140.53 175.52 112.49 128.97 165.78 119.11 77.52 156.13
Cash Conversion Cycle -24.81 -28.10 -19.10 -31.25 -6.12 89.59 151.47 102.28
Working Capital Days 6.08 31.05 26.89 -2.94 -0.63 124.11 163.60 136.85
ROCE % 15.53% 18.72% 54.66% 29.74% 19.78% 11.43% 12.19%

Insights

In beta
Mar 2023 Mar 2024 Mar 2025
Export Market Reach
Countries

Log in to view insights

Please log in to see hidden values.

Login
Installed Capacity - Capsules (Sotac Pharma)
Crore per year
Installed Capacity - Tablets (Sotac Healthcare)
Crore per year
Installed Capacity - Tablets (Sotac Pharma - Standalone)
Crore per year
Number of Corporate Clients
Number
R&D Scientists
Number
Total Full-time Employees
Number
Manufacturing Permissions - Sotac Pharma
Number of Products
Products sold in US Market
Number

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

3 Recently
Apr 2023Sep 2023Mar 2024Sep 2024Mar 2025Sep 2025Mar 2026
72.85% 72.85% 72.85% 72.85% 72.85% 72.85% 72.85%
12.88% 8.51% 8.99% 8.88% 15.12% 16.14% 16.79%
0.00% 0.00% 0.00% 0.00% 0.68% 0.00% 0.00%
14.27% 18.64% 18.16% 18.27% 11.35% 11.01% 10.36%
No. of Shareholders 784255245251243240221

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports